Back to top

Image: Bigstock

Nikon Corporation

Read MoreHide Full Article

Nikon shares have underperformed the industry in the past year. High R&D expenditure, restructuring costs and investments related to the medical business continues to drag down margins. Nevertheless, the company benefits from strong performance of precision and healthcare segments. Moreover, improving demand for D850, Z 7 and D3500 cameras are expected to boost top-line growth. Additionally, international revenue growth from biological microscopes and retinal imaging diagnosis instruments are expected to aid healthcare revenues.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nikon Corp. (NINOY) - free report >>

Published in